Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 cemiplimab monotherapy in advanced cutaneous squamous cell carcinoma
2016-000105-36Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC) (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Objective response rate. Started Apr 2016; status: completed.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2016-000105-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000105-36.